CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy

Antibody–drug conjugates in gastric cancer: from targeted cytotoxicity to immune modulation

Next-generation ADCs may function not only as targeted cytotoxic agents but also as modulators of antitumor immunity in gastric cancer, and integrating tumor-antigen biology with immune-contextual features may enable more rational patient selection and therapeutic combinations.

CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors

Results suggest that CRB-701 may be a promising alternative therapeutic for the treatment of nectin-4 expressing tumors, providing a more favorable therapeutic window and potentially enabling regimens with higher doses and less frequent dosing than are required for EV, the only currently approved nectin-4 targeting ADC...

Combination Of Bispecific Antibodies Enable Targeted TNFRSF Agonism and Effective Antitumor Activity.

4-1BB is an inducible costimulatory molecule that requires receptor clustering to boost anti-cancer immune response. However, the clinical development of monoclonal antibodies targeting 4-1BB has been constrained by toxicities driven by systemic activation. To address this, bispecific antibodies (bsAbs) have been devel...

Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

Antibody-drug conjugates (ADCs) show clinical efficacy against several solid malignancies, inducing cytotoxic effects in malignant cells accompanied by changes in the composition of the tumor stroma. The therapeutic effects of some ADCs have been shown to be potentiated by combination with anti-PD(L)1 checkpoint inhibi...

Direct Tumor Suppression by Anti-Basigin Antibody and Enhancement of Macrophage-Mediated Cancer Cell Phagocytosis under SIRPα Blockade.

Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors.

Immune checkpoint inhibitors (ICIs) have improved cancer outcomes; however, many patients fail to respond, highlighting the need for novel targets. HVEM (Herpes Virus Entry Mediator) is an immune regulator with both inhibitory and stimulatory functions, making it a promising therapeutic candidate. We have developed Ant...